Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections

Mokhtary, Pardis; Pourhashem, Zeinab; Mehrizi, Akram Abouie; Sala, Claudia; Rappuoli, Rino

doi:10.3390/biomedicines10081861

Cited by 14 publications

(7 citation statements)

References 205 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14–16 mAbs are synthetic neutralizing antibodies designed to act directly and specifically on a certain part of a pathogen, acting like an antibody and providing passive immunization. 3 , 4 , 17 …”

Section: Discussionmentioning

confidence: 99%

Immunization technologies: Time to consider new preventative solutions for respiratory syncytial virus infections

Weil-Olivier

Nolan

Navarro-Alonso³

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

New technologies for the prevention of infectious diseases are emerging to address unmet medical needs, in particular, the use of long-acting monoclonal antibodies (mAb) to prevent Respiratory Syncytial Virus (RSV) lower respiratory tract disease in infants during their first RSV season. The lack of precedent for mAbs for broad population protection creates challenges in the assessment of upcoming prophylactic long-acting mAbs for RSV, with associated consequences in legislative and registration categorization, as well as in recommendation, funding, and implementation pathways. We suggest that the legislative and regulatory categorization of preventative solutions should be decided by the effect of the product in terms of its impact on the population and health-care systems rather than by the technology used or its mechanism of action. Immunization can be passive and active, both having the same objective of prevention of infectious diseases. Long-acting prophylactic mAbs work as passive immunization, as such, their recommendations for use should fall under the remit of National Immunization Technical Advisory Groups or other relevant recommending bodies for inclusion into National Immunization Programs. Current regulations, policy, and legislative frameworks need to evolve to embrace such innovative preventative technologies and acknowledge them as one of key immunization and public health tools.

show abstract

Section: Discussionmentioning

confidence: 99%

Immunization technologies: Time to consider new preventative solutions for respiratory syncytial virus infections

Weil-Olivier

Nolan

Navarro-Alonso³

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…As such, monoclonal antibodies (mAbs) targeted against a single target may potentially be the game changer in the treatment of sepsis. With cancer [ 51 ] and viral [ 52 , 53 ] infections taking the majority of the limelight, the use of mAbs in the treatment of bacterial infection is still very young with only three FDA-approved drugs so far [ 15 ]. Monoclonal antibodies may provide benefits through two major strategies: (1) monoclonal antibodies targeting the pathogen and its components, and (2) mAbs targeting inflammatory signaling may directly suppress the production of inflammatory mediators.…”

Section: Current Therapeutic Approaches To Treat Sepsismentioning

confidence: 99%

Recent Advances in Monoclonal Antibody-Based Approaches in the Management of Bacterial Sepsis

2023

View full text Add to dashboard Cite

Sepsis is a life-threatening condition characterized by an uncontrolled inflammatory response to an infectious agent and its antigens. Immune cell activation against the antigens causes severe distress that mediates a strong inflammatory response in vital organs. Sepsis is responsible for a high rate of morbidity and mortality in immunosuppressed patients. Monoclonal antibody (mAb)-based therapeutic strategies are now being explored as a viable therapy option for severe sepsis and septic shock. Monoclonal antibodies may provide benefits through two major strategies: (a) monoclonal antibodies targeting the pathogen and its components, and (b) mAbs targeting inflammatory signaling may directly suppress the production of inflammatory mediators. The major focus of mAb therapies has been bacterial endotoxin (lipopolysaccharide), although other surface antigens are also being investigated for mAb therapy. Several promising candidates for mAbs are undergoing clinical trials at present. Despite several failures and the investigation of novel targets, mAb therapy provides a glimmer of hope for the treatment of severe bacterial sepsis and septic shock. In this review, mAb candidates, their efficacy against controlling infection, with special emphasis on potential roadblocks, and prospects are discussed.

show abstract

“…MoAbs specific for pathogen’s antigens have recently been introduced for passive immunotherapy of infectious diseases for which an effective vaccine is not yet available, as RSV, or if the vaccine is poorly used and/or scarcely protective, as anthrax, or finally in addition to the vaccine, but with a different indication [ 70 , 71 ].…”

Section: Diagnostic Tools Antibiotics Antivirals Monoclonal Antibodie...mentioning

confidence: 99%

Have Diagnostics, Therapies, and Vaccines Made the Difference in the Pandemic Evolution of COVID-19 in Comparison with “Spanish Flu”?

Lista

Peragallo²,

Biselli

et al. 2023

Pathogens

View full text Add to dashboard Cite

In 1918 many countries, but not Spain, were fighting World War I. Spanish press could report about the diffusion and severity of a new infection without censorship for the first-time, so that this pandemic is commonly defined as “Spanish flu”, even though Spain was not its place of origin. “Spanish flu” was one of the deadliest pandemics in history and has been frequently compared with the coronavirus disease (COVID)-19 pandemic. These pandemics share similarities, being both caused by highly variable and transmissible respiratory RNA viruses, and diversity, represented by diagnostics, therapies, and especially vaccines, which were made rapidly available for COVID-19, but not for “Spanish flu”. Most comparison studies have been carried out in the first period of COVID-19, when these resources were either not yet available or their use had not long started. Conversely, we wanted to analyze the role that the advanced diagnostics, anti-viral agents, including monoclonal antibodies, and innovative COVID-19 vaccines, may have had in the pandemic containment. Early diagnosis, therapies, and anti-COVID-19 vaccines have markedly reduced the pandemic severity and mortality, thus preventing the collapse of the public health services. However, their influence on the reduction of infections and re-infections, thus on the transition from pandemic to endemic condition, appears to be of minor relevance. The high viral variability of influenza and coronavirus may probably be contained by the development of universal vaccines, which are not easy to be obtained. The only effective weapon still remains the disease prevention, to be achieved with the reduction of promiscuity between the animal reservoirs of these zoonotic diseases and humans.

show abstract

Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections

Cited by 14 publications

References 205 publications

Immunization technologies: Time to consider new preventative solutions for respiratory syncytial virus infections

Immunization technologies: Time to consider new preventative solutions for respiratory syncytial virus infections

Recent Advances in Monoclonal Antibody-Based Approaches in the Management of Bacterial Sepsis

Have Diagnostics, Therapies, and Vaccines Made the Difference in the Pandemic Evolution of COVID-19 in Comparison with “Spanish Flu”?

Contact Info

Product

Resources

About